HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Enterobacteriaceae Infections

Subscribe to New Research on Enterobacteriaceae Infections

Infections with bacteria of the family ENTEROBACTERIACEAE.

Also Known As:

Infections, Enterobacteriaceae; Infections, Enterobacterial; Enterobacteriaceae Infection; Enterobacterial Infection; Infection, Enterobacteriaceae; Infection, Enterobacterial; Enterobacterial Infections

Networked: 53 relevant articles (4 outcomes, 4 trials/studies)

Relationship Network

Disease Context: Research Results

Bacterial Infections and Mycoses
- Bacterial Infections: 10283
  - Gram-Negative Bacterial Infections: 350
    - Enterobacteriaceae Infections: 53

Related Diseases

1.	Pyelonephritis
2.	Critical Illness (Critically Ill)
3.	Streptococcal Infections (Streptococcal Infection)
4.	Rheumatic Fever (Acute Articular Rheumatism)
5.	Infection

Experts

1.	Dal-Paz, Karine: 2 articles (01/2011 - 05/2009)
2.	Paterson, David L: 2 articles (06/2006 - 06/2006)
3.	Carroll, Karen C: 1 article (12/2015)
4.	Vilasoa, Mercedes: 1 article (12/2015)
5.	Hsu, Alice J: 1 article (12/2015)
6.	Cosgrove, Sara E: 1 article (12/2015)
7.	Tamma, Pranita D: 1 article (12/2015)
8.	Avdic, Edina: 1 article (12/2015)
9.	Milstone, Aaron M: 1 article (12/2015)
10.	Investigation and Surveillance of Healthcare-Associated Infections Network (RAISIN)/multidrug resistance study group: 1 article (09/2015)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Enterobacteriaceae Infections:

1.	Cefotaxime (Kendrick)FDA LinkGeneric 02/26/1981 - "[Cefotaxime treatment of 25 cases of severe enterobacteriaceae infections in an intensive care unit (author's transl)]." 05/01/2015 - "This study was performed to compare the therapeutic efficacy of cefuroxime with that of cefotaxime as initial antimicrobial therapies in women with complicated nonobstructive acute pyelonephritis (APN) caused by Enterobacteriaceae infections. " 05/01/2015 - "Propensity-matched analysis to compare the therapeutic efficacies of cefuroxime versus cefotaxime as initial antimicrobial therapy for community-onset complicated nonobstructive acute pyelonephritis due to Enterobacteriaceae infection in women."
2.	Ticarcillin (Tarcil)FDA Link 12/01/1987 - "Though the pharmacokinetic behaviour of TICAR and CLA is not similar, yet based on the therapeutically optimal concentrations of CLA and TICAR reached in serum, Timentin at the dose used in the present study should be effective in treating most TICAR-resistant Enterobacteriaceae infections in dogs. "
3.	Polymyxins (Polymyxin)IBA 03/01/2015 - "Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis." 03/01/2015 - "Future large-volume, well-designed randomized control trials are required to determine the role of polymyxins in treating carbapenem-resistant Enterobacteriaceae infections. " 03/01/2015 - "Our results suggest that polymyxins may be as efficacious as other antimicrobial therapies for the treatment of carbapenem-resistant Enterobacteriaceae infection. "
4.	Cefuroxime (Zinacef)FDA LinkGeneric 05/01/2015 - "This study was performed to compare the therapeutic efficacy of cefuroxime with that of cefotaxime as initial antimicrobial therapies in women with complicated nonobstructive acute pyelonephritis (APN) caused by Enterobacteriaceae infections. " 05/01/2015 - "Propensity-matched analysis to compare the therapeutic efficacies of cefuroxime versus cefotaxime as initial antimicrobial therapy for community-onset complicated nonobstructive acute pyelonephritis due to Enterobacteriaceae infection in women."
5.	ticarcillin-clavulanic acid (Timentin)FDA Link 12/01/1987 - "Though the pharmacokinetic behaviour of TICAR and CLA is not similar, yet based on the therapeutically optimal concentrations of CLA and TICAR reached in serum, Timentin at the dose used in the present study should be effective in treating most TICAR-resistant Enterobacteriaceae infections in dogs. "
6.	sulfonated IgGIBA 01/01/1985 - "A sulfonated IgG preparation (S-sIgG) and the enzymatically derived fragments F(ab')2 and Fab/Fc were opsonic in vitro and provided in vivo protection against lethal enterobacterial infection in mice. "
7.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/06/1999 - "Several recent studies have reported that mast cells play a critical role in innate immunity in mice by releasing tumor necrosis factor alpha (TNF-alpha) to recruit neutrophils to sites of enterobacterial infection. "
8.	ertapenem (Invanz)FDA Link 01/01/2011 - "Ertapenem was mandated for ESBL-producing Enterobacteriaceae infections in the absence of non-fermenting Gram-negative bacilli (GNB) from April 2006 to March 2008. " 07/01/2011 - "Cases were adults with a culture-confirmed Enterobacteriaceae infection with reduced susceptibility to meropenem or ertapenem. " 05/01/2009 - "The use of ertapenem was mandated for treatment of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in the absence of nonfermenting gram-negative bacilli for 1 year. " 12/01/2010 - "Risk factors for ertapenem-resistant Enterobacteriaceae infection included intensive care unit stay (odds ratio [OR], 4.6 [95% confidence interval {CI}, 2.0-10.3]), vancomycin-resistant Enterococcus colonization (OR, 7.1 [95% CI, 2.4-21.4]), prior central venous catheter use (OR, 10.0 [95% CI, 3.0-33.1]), prior receipt of mechanical ventilation (OR, 5.8 [95% CI, 2.1-16.2]), exposure to any antibiotic during the 30 days prior to a positive culture result (OR, 18.5 [95% CI, 4.9-69.9]), use of a β-lactam during the 30 days prior to a positive culture result (OR, 6.9 [95% CI, 3.0-16.0], and use of a carbapenem during the 30 days prior to a positive culture result (OR, 18.2 [95% CI, 2.6-130.0]). " 05/01/2009 - "We sought to evaluate the indirect impact of ertapenem use for the treatment of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in our hospital on the susceptibility of Pseudomonas aeruginosa to imipenem. "
9.	Carbapenems (Carbapenem Antibiotics)IBA 01/01/2007 - "aeruginosa to members of the Enterobacteriaceae family is very worrisome because the rapid and wide dissemination of these potent antimicrobial resistance mechanisms could jeopardize the clinical use of carbapenems for the treatment of multidrug-resistant Enterobacteriaceae infections." 06/01/2006 - "The vast majority of Enterobacteriaceae, including ESBL producers, remain susceptible to carbapenems, and these agents are considered preferred empiric therapy for serious Enterobacteriaceae infections. " 06/01/2006 - "The vast majority of Enterobacteriaceae, including ESBL producers, remain susceptible to carbapenems, and these agents are considered preferred empiric therapy for serious Enterobacteriaceae infections. " 02/01/2010 - "Therefore, carbapenems (imipenem, meropenem, ertapenem) may become inefficient for treating enterobacterial infections with KPC-producing bacteria, which are in addition resistant to many other non beta-lactam molecules, leaving only few available therapeutic options. " 04/01/2009 - "Carbapenems (imipenem, meropenem, and ertapenem) may thus become inefficient for treating enterobacterial infections with KPC-producing bacteria, which are, in addition, resistant to many other non-beta-lactam molecules, leaving few available therapeutic options. "
10.	Imipenem FDA Link 01/01/2015 - "We conducted a single-center retrospective matched-cohort analysis in adult patients with Enterobacteriaceae infections treated with meropenem, imipenem, or doripenem. " 05/01/2009 - "We sought to evaluate the indirect impact of ertapenem use for the treatment of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in our hospital on the susceptibility of Pseudomonas aeruginosa to imipenem. " 02/01/2010 - "Therefore, carbapenems (imipenem, meropenem, ertapenem) may become inefficient for treating enterobacterial infections with KPC-producing bacteria, which are in addition resistant to many other non beta-lactam molecules, leaving only few available therapeutic options. " 04/01/2009 - "Carbapenems (imipenem, meropenem, and ertapenem) may thus become inefficient for treating enterobacterial infections with KPC-producing bacteria, which are, in addition, resistant to many other non-beta-lactam molecules, leaving few available therapeutic options. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/1968 - "The chemotherapy of enterobacterial infections." 07/01/2010 - "These enzymes have the capacity to hydrolyze broad-spectrum cephalosporins and are greatly used for antimicrobial chemotherapy on enterobacterial infections. "
2.	Catheters 12/01/2010 - "Risk factors for ertapenem-resistant Enterobacteriaceae infection included intensive care unit stay (odds ratio [OR], 4.6 [95% confidence interval {CI}, 2.0-10.3]), vancomycin-resistant Enterococcus colonization (OR, 7.1 [95% CI, 2.4-21.4]), prior central venous catheter use (OR, 10.0 [95% CI, 3.0-33.1]), prior receipt of mechanical ventilation (OR, 5.8 [95% CI, 2.1-16.2]), exposure to any antibiotic during the 30 days prior to a positive culture result (OR, 18.5 [95% CI, 4.9-69.9]), use of a β-lactam during the 30 days prior to a positive culture result (OR, 6.9 [95% CI, 3.0-16.0], and use of a carbapenem during the 30 days prior to a positive culture result (OR, 18.2 [95% CI, 2.6-130.0]). "
3.	Sternotomy 08/01/2013 - "A case-control study was conducted to search specifically for risk factors for Enterobacteriaceae infections after median sternotomy in cardiac patients. "
4.	Transplantation (Transplant Recipients) 03/15/2014 - "Extended spectrum β-lactamase-producing Enterobacteriaceae infection in heart and lung transplant recipients and in mechanical circulatory support recipients."
5.	Artificial Respiration (Mechanical Ventilation) 12/01/2010 - "Risk factors for ertapenem-resistant Enterobacteriaceae infection included intensive care unit stay (odds ratio [OR], 4.6 [95% confidence interval {CI}, 2.0-10.3]), vancomycin-resistant Enterococcus colonization (OR, 7.1 [95% CI, 2.4-21.4]), prior central venous catheter use (OR, 10.0 [95% CI, 3.0-33.1]), prior receipt of mechanical ventilation (OR, 5.8 [95% CI, 2.1-16.2]), exposure to any antibiotic during the 30 days prior to a positive culture result (OR, 18.5 [95% CI, 4.9-69.9]), use of a β-lactam during the 30 days prior to a positive culture result (OR, 6.9 [95% CI, 3.0-16.0], and use of a carbapenem during the 30 days prior to a positive culture result (OR, 18.2 [95% CI, 2.6-130.0]). "